GlassScriptPhysician profile
Ala' Arafah
NPI 1528630985
$211.16
in general payments reported to CMS, 2019-2025
7 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $211.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $55.15 | 2025 | Livtencity |
| Novartis Pharmaceuticals Corporation | $42.79 | 2025 | |
| Alnylam Pharmaceuticals INC. | $25.46 | 2025 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $22.90 | 2025 | Evkeeza |
| Novo Nordisk INC | $22.51 | 2025 | Wegovy |
| Bridgebio Pharma, INC. | $22.11 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $20.24 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ala' Arafah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.